Merck Plans Lantus Follow-On This Year, Releases Phase III Data At ADA
This article was originally published in The Pink Sheet Daily
Merck released positive Phase III data on its follow-on biologic, insulin glargine, for diabetes at the American Diabetes Association Scientific Sessions, positioning the insulin category for fierce pricing competition.
You may also be interested in...
Samsung Bioepis will be responsible for development, manufacturing and registration, while Merck will be responsible for commercializing any resulting drugs. Merck says the partnership will complement the firm’s internal biologics portfolio.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.